234 related articles for article (PubMed ID: 19864234)
41. A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): a case report.
Gozzetti A; Cerase A; Crupi R; Raspadori D; Defina M; Bocchia M; Lauria F
Leuk Res; 2011 Nov; 35(11):e206-8. PubMed ID: 21767877
[No Abstract] [Full Text] [Related]
42. Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement.
Cho YU; Chi HS; Park CJ; Jang S; Seo EJ; Huh J
Am J Clin Pathol; 2009 May; 131(5):640-6. PubMed ID: 19369622
[TBL] [Abstract][Full Text] [Related]
43. Establishment and biological characteristics of human multiple myeloma cell line CZ-1.
Hou J; Lin FY; Zhang B; Zhang LZ; Ding SQ
Chin Med J (Engl); 2004 Jan; 117(1):115-9. PubMed ID: 14733786
[TBL] [Abstract][Full Text] [Related]
44. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.
Wei A; Westerman D; Feleppa F; Trivett M; Juneja S
Haematologica; 2005 Aug; 90(8):1147-9. PubMed ID: 16079123
[TBL] [Abstract][Full Text] [Related]
45. Bone marrow plasmacytosis in idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia: a report of four cases.
Kojima M; Murayama K; Igarashi T; Masawa N; Shimano S; Nakamura S
Pathol Res Pract; 2007; 203(11):789-94. PubMed ID: 17904300
[TBL] [Abstract][Full Text] [Related]
46. The prevalence and clinical implications of c-kit expression in plasma cell myeloma.
Pruneri G; Ponzoni M; Ferreri AJ; Freschi M; Tresoldi M; Baldini L; Mattioli M; Agnelli L; Govi S; Mancuso P; Agazzi A; Bertolini F; Peccatori J; Bosari S; Gianelli U; Viale G; Neri A
Histopathology; 2006 Apr; 48(5):529-35. PubMed ID: 16623778
[TBL] [Abstract][Full Text] [Related]
47. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow.
Okcu MF; Wang RY; Bueso-Ramos C; Schober W; Weidner D; Andrassy R; Blakely M; Russell H; Ozkan A; Kuttesch J; Andreeff M; Chan KW; Ater J
Pediatr Blood Cancer; 2005 Nov; 45(6):787-95. PubMed ID: 15929127
[TBL] [Abstract][Full Text] [Related]
48. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
49. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
[TBL] [Abstract][Full Text] [Related]
50. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
51. Contribution of neural cell adhesion molecule (NCAM) to hemopoietic system in monkeys.
Kato J; Hisha H; Wang XL; Mizokami T; Okazaki S; Li Q; Song CY; Maki M; Hosaka N; Adachi Y; Inaba M; Ikehara S
Ann Hematol; 2008 Oct; 87(10):797-807. PubMed ID: 18575864
[TBL] [Abstract][Full Text] [Related]
52. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
[TBL] [Abstract][Full Text] [Related]
53. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.
Bataille R; Jégo G; Robillard N; Barillé-Nion S; Harousseau JL; Moreau P; Amiot M; Pellat-Deceunynck C
Haematologica; 2006 Sep; 91(9):1234-40. PubMed ID: 16956823
[TBL] [Abstract][Full Text] [Related]
54. [Unusual presentation of plasma cell myeloma].
Bürgesser MV; Basquiera AL; Diller A
Medicina (B Aires); 2012; 72(3):251-4. PubMed ID: 22763165
[TBL] [Abstract][Full Text] [Related]
55. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma.
Douds JJ; Long DJ; Kim AS; Li S
J Clin Pathol; 2014 Sep; 67(9):792-6. PubMed ID: 24958785
[TBL] [Abstract][Full Text] [Related]
57. Minimal residual disease monitoring in multiple myeloma.
Davies FE; Rawstron AC; Owen RG; Morgan GJ
Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
[TBL] [Abstract][Full Text] [Related]
58. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
Schouweiler KE; Karandikar NJ; Holman CJ
Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
[TBL] [Abstract][Full Text] [Related]
59. Immunophenotype of neoplastic plasma cells in AL amyloidosis.
Deshmukh M; Elderfield K; Rahemtulla A; Naresh KN
J Clin Pathol; 2009 Aug; 62(8):724-30. PubMed ID: 19638544
[TBL] [Abstract][Full Text] [Related]
60. Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival.
Leleu X; Genevieve F; Guieze R; Duhamel A; Andrieux J; Berthon C; Godon A; Prat-Lesaffre S; Depil S; Lai JL; Facon T; Zandecki M;
Leuk Res; 2005 Jun; 29(6):665-71. PubMed ID: 15863207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
